The reaffirmation of the Outperform rating and increase in price target by Baird analyst Eric Coldwell is a strong positive signal for Medpace Holdings. This suggests confidence in the company's future performance and growth prospects, likely leading to increased investor interest and potentially a rise in stock price in the short term.